Searchable abstracts of presentations at key conferences in endocrinology

ea0065p262 | Metabolism and Obesity | SFEBES2019

Audit on sodium glucose cotransporter-2 inhibitors (SGLT2) at Nottingham University Hospitals

Vyas Abhishek , Yahia Seif , Mendis Buddhike

Aims/objectives: The aims of the audit were to assess if Sodium Glucose Cotransporter-2 inhibitors (SGLT2) were initiated in accordance with National institute of clinical excellence guidelines and appropriate effectiveness and reviews were performed in accordance with these guidelines.Methods: A retrospective audit of 31 patients with Type 2 diabetes prescribed Sodium Glucose Cotransporter-2 inhibitors (SGLT2) between March 2014 and January 2017 at Nott...

ea0037ep338 | Diabetes (pathiophysiology & epitemiology) | ECE2015

Pancreatogenic diabetes

Yahia Seif eldin , Mendis Budd , Crabtree Tom , Seevaratnam Nandini

Aims: Diabetes mellitus secondary to pancreatic disease and pancreatic surgery (pancreatogenic; type 3c) is a discrete entity to common types of diabetes and there are no well established guidelines for its management. At Nottingham University Hospitals, we have set up a multidisciplinary pancreatogenic diabetes clinic since 2008. The aim of this study is to look at the outcome of the clinic since itÂ’s been established.Methods: Case notes and hospit...

ea0062cb3 | Additional Cases | EU2019

Endocrinopathies post immune check point inhibitors

Hamza Malak , Van Heeswijk Isabelle , Yahia Seif , Fernando Devaka , Abdulla Haitham , Muraleedharan Vakkat

Introduction: Immune adverse related events are commonly recognized complications of immune check point inhibitors. Here we identify multiple endocrinopathies occurring concurrently in the same patient. In addition to highlighting the common immune adverse effects seen in other cases.Case 1: 33F Refractory Hodgkins Lymphoma tried on several therapies. She was started on Nivolumab (PD-1) with remarkable response. She developed symptoms of Amenorrhea, gala...

ea0063p340 | Thyroid 1 | ECE2019

Endocrinopathies post Immune check point inhibitors

Hamza Malak , Van Heeswijk Isabelle , Yahia Seif , Fernando Devaka , Abdulla Haitham , Muraleedharan Vakkat

Introduction: Immune adverse related events are commonly recognized complications of immune check point inhibitors. Here we identify multiple endocrinopathies occurring concurrently in the same patient. In addition to highlighting the common immune adverse effects seen in other cases.Case 1: 33F Refractory Hodgkins Lymphoma tried on several therapies. She was started on Nivolumab (PD-1) with remarkable response. She developed symptoms of Amenorrhea, gala...